Economic Evaluation of Dupilumab versus Endoscopic Sinus Surgery for the Treatment of Chronic Rhinosinusitis with Nasal Polyps

ConclusionsWhile dupilumab and ESS may demonstrate similar clinical effectiveness, ESS remains the most cost-effective treatment option and should remain standard of care for CRSwNP patients refractory to medical therapy.This article is protected by copyright. All rights reserved

Source: International Forum of Allergy and Rhinology - December 7, 2021 Category: Allergy & Immunology Authors: Arjun K. Parasher, Matt Gliksman, Daniel Segarra, Theodore Lin, Luke Rudmik, Troy Quast Tags: ORIGINAL ARTICLE Source Type: research